3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
12
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
9
Leukemia, Myeloid, Acute
7
Lymphoma
5
Leukemia
5
Lymphoma, Non-Hodgkin
4
Leukemia, Biphenotypic, Acute
4
Squamous Cell Carcinoma of Head and Neck
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Stomach Neoplasms
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, B-Cell
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Anemia, Refractory, with Excess of Blasts
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Paclitaxel
113
Carboplatin
99
Bevacizumab
59
pembrolizumab
56
liposomal doxorubicin
56
Gemcitabine
42
olaparib
39
Topotecan
33
niraparib
29
Nivolumab
21
Cisplatin
21
Doxorubicin
17
Cyclophosphamide
17
1-dodecylpyridoxal
16
Drug Therapy
15
Docetaxel
15
avelumab
13
Fulvestrant
11
oregovomab
10
Oxaliplatin
10
rucaparib
9
fludarabine
9
Injections
9
Fluorouracil
9
veliparib
8
mirvetuximab soravtansine
8
atezolizumab
8
Cetuximab
8
fluzoparib
7
cemiplimab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ovarian Neoplasms
×
fludarabine phosphate
×
Clear all
NCT02876510
2025-02-04
ACTolog
Immatics US, Inc.
Phase 1
Completed
38 enrolled